More hair loss treatment blogs

Hair loss blog at peterproctor.com

Hair loss blog at drproctor.com

Hair loss blog at md.st

Hair loss blog

More hair regrowth blogs

Hair loss and hair loss treatment

Dr Proctor remarks: This is a good confirmation of the partial efficacy of an old treatment for hair loss in alopecia areata.

Photodermatol Photoimmunol Photomed. 2011 Dec;27(6):325-7. doi: 10.1111/j.1600-0781.2011.00612.x.

Narrowband ultraviolet B phototherapy for alopecia areata.

Bayramgürler D,
Abstract

Although narrowband ultraviolet B (NB UV phototherapy is a well-established treatment in many dermatosis, there is little evidence of efficacy of this method for alopecia areata (AA) hair loss treatment in the literature. We undertook a retrospective review of the 25 AA patients treated with NB UVB. Intramuscular triamcinolone acetonide injections per month were used as concomitant treatment in some patients who did not have any contraindication. Eight patients (32%) received monthly intramuscular corticosteroid injections. Four (22.2%) and two (20%) patients achieved excellent response in extensive patchy hair loss patients and entire scalp hair loss patients, respectively. Four of six patients who achieved excellent response also received monthly intramuscular corticosteroid injections. When patients receiving systemic corticosteroid injections were compared with patients given only NB UVB with respect to the treatment responses, a statistically significant difference was seen in patients who achieved excellent response. NB UVB is not an effective treatment with only 20% excellent treatment responses in patients with severe AA, most of whom were also treated with systemic corticosteroids.

Edited for blog use

List of Hair loss treatment blogs

Hair loss blog at b2.ce.st

Hair loss blog b2.tx.st

More hair regrowth blogs

Hair loss and hair loss treatment

List of Hair loss treatment blogs

Hair loss blog at b2.ce.st

Hair loss blog b2.tx.st

More hair regrowth blogs

Hair loss and hair loss treatment

J Dtsch Dermatol Ges. 2011 Oct;9 Suppl 6:S1-57. doi: 10.1111/j.1610-0379.2011.07802.x.

Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men.

Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, Trakatelli M, Finner A, Kiesewetter F, Trüeb R, Rzany B, Blume-Peytavi U; European Dermatology Forum (EDF).

Source

Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Charité- Universitätsmedizin, Berlin, Germany.

Abstract

Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 % Caucasian men and 42 % of women. Patients diagnosed with androgenetic alopecia may undergo significant impairment of quality of life. Despite the high prevalence and the variety of therapeutic options available, there have been no national or international evidence-based guidelines for the treatment of androgenetic alopecia in men and women so far. Therefore, the European Dermatology Forum (EDF) initiated a project to develop an evidence-based S3 guideline for the treatment of andro-genetic hair loss. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists as well as general practitioners with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia.

Dr Proctor notes: The hair los here is from hair cells in the inner ear. Sort of bragging– we were the first to show that oxidative stress plays a role in the toxicity of the anticancer drug cis-platinum.

It is also interesting that hydrogen gas (which is produced in large amounts by intestinal bacteria) is a good antioxidant. Maybe flatulence really is good for you.

Int J Pediatr Otorhinolaryngol. 2011 Nov 2. [Epub ahead of print]

Inhalation of hydrogen gas attenuates cisplatin-induced ototoxicity via reducing oxidative stress.

Abstract

OBJECTIVE:

Cisplatin, an anticancer drug used extensively to treat a broad range of tumors, has strong ototoxic side effects induced by reactive oxygen species (ROS). Recently, it has been reported that hydrogen gas (H(2)) is a new antioxidant by selectively reducing hydroxyl radical, the most cytotoxic ROS. The present study was designed to investigate whether H(2) treatment is beneficial to cisplatin-induced ototoxicity via reducing oxidative stress.

METHODS:

The animals were intraperitoneally given a 30min infusion of 16mg/kg cisplatin or the same volume of saline. H(2) treatment was given twice with 2% H(2) inhalation for 60min starting at 1h and 6h after cisplatin or saline injection, respectively. The hearing status of all animals was evaluated by auditory brainstem responses (ABR). The hair cell damage was observed by phalloidin staining. In addition, the levels of oxidative products in serum and cochlear tissue were measured.

RESULTS:

We found that H(2) treatment significantly attenuated cisplatin-induced hearing loss evaluated by click-evoked and tone burst ABR threshold. Furthermore, histological analysis revealed that 2% H(2) treatment significantly alleviated cisplatin-induced hair cell damage in the organ of corti. In addition, cisplatin significantly increased the levels of malondialdehyde (MDA) and 8-iso-prostaglandin F2á (8-iso-PGF2á) in serum and cochlear tissue, which was attenuated by H(2) treatment.

CONCLUSION:

These results demonstrate that H(2) is beneficial to cisplatin-induced ototoxicity via reducing oxidative stress. Therefore, H(2) has potential for improving the quality of life of patients during chemotherapy by efficiently mitigating the cisplatin ototoxicity.

Keywords: cognitive engineering, flatulence, hair loss, cis-platinum deafness.

cognitive engineering

Hair Loss Treatment

J Proteome Res. 2010 Aug 19. [Epub ahead of print]

Trichohyalin is a Potential Major Autoantigen in Human Alopecia Areata.
Leung MC, Sutton CW, Fenton DA, Tobin DJ.

Abstract
Several lines of evidence support an autoimmune basis for alopecia areata (AA), a common putative autoimmune hair loss disorder. However, definitive support is lacking largely because the identity of hair follicle (HF) autoantigen(s) involved in its pathogenesis remains unknown. Here, we isolated AA-reactive HF-specific antigens from normal human scalp anagen HF extracts by immunoprecipitation using serum antibodies from 10 AA patients. Samples were analyzed by LC-MALDI-TOF/TOF mass spectrometry, which indicated strong reactivity to the hair regrowth phase-specific structural protein trichohyalin in all AA sera. Keratin 16 (K16) was also identified as another potential AA-relevant target HF antigen. Double immunofluorescence studies using AA (and control sera) together with a monoclonal antibody to trichohyalin revealed that AA sera contained immunoreactivity that colocalized with trichohyalin in the growth phase-specific inner root sheath of HF. Furthermore, a partial colocalization of AA serum reactivity with anti-K16 antibody was observed in the outer root sheath of the HF. In summary, this study supports the involvement of an immune response to anagen-specific HFs antigens in AA and specifically suggests that an immune response to trichohyalin and K16 may have a role in the pathogenesis of the enigmatic disorder.

edited for hair loss blog

Hair Loss Treatment

Indian J Dermatol. 2010 Apr–Jun; 55(2): 148.

COMPARATIVE ASSESSMENT OF TOPICAL STEROIDS, TOPICAL TRETENOIN (0.05%) AND DITHRANOL PASTE IN ALOPECIA AREATA

Sudip Das, et al

There have been various controversial reports regarding the efficacy of topical agents in topical treatment of hair loss due to alopecia areata.

The study aims to find out the effective treatments.

Eighty patients were chosen from the skin OPD of Bankura Sammilani Medical College, Bankura, West Bengal, after evaluating the exclusion criterions. Treatments were continued for 3 month period and a follow up after further 3 months. After dividing them into four groups–group-I (topical steroids), group-II (topical tretinoin 0.05%) group-III (dithranol paste 0.25%), and group-IV (white soft petrolatum jelly)–patients were evaluated.Results:
Seventy percent of group-I, 55% of group-II, 35% of group-III, and 20% of the control group (white soft petrolatum jelly) responded favorably. Side effects in the form of dermatitis and hyperpigmentation were seen in group-III. However, no patient discontinued from the study.

We conclude that both topical steroids and tretinoin were fairly effective in limited variant of alopecia areata.

Keywords: Hair loss hair regrowth hai rloss treatment Alopecia areata, anthralin, topical steroids, tretenoin

edited for hair loss blog

Dermatol Online J. 2010 Feb 15;16(2):3.

Does D matter? The role of vitamin D in hair disorders and hair follicle cycling.
Amor KT, et al

Conclusion
Extensive data from animal models clearly show that the VDR, independent of vitamin D3 hormone, plays an important role in the hair follicle cycle, specifically anagen initiation. Studies have demonstrated the ability of vitamin D3 analogs to stimulate hair regrowth, but clinical trials of calcitriol in humans have been unable to replicate these results. Reasons for this may be that more potent analogs of vitamin D3 were used in the animal studies than the human trials. Also, the mechanism of hair recovery in nude mice may not be applicable to humans with alopecia. The latter is reflected in one study that used nude mice with congenital alopecia, which does not have an equivalent in humans. This review shows the need for further exploration of the role of vitamin D and the VDR in the hair cycle. For clinical hair disorders in which there is an abnormal hair cycle, such as chemotherapy-induced alopecia, treatments that up regulate the expression of the vitamin D receptor may be successful. Developments of such treatments are a future area of study. Furthermore, studies on the optimal levels of local and systemic vitamin D levels are still limited and there is currently no evidence-based data to recommend vitamin D supplementation for various types of hair loss. In order to fully understand the effects of vitamin D supplementation in alopecia, future studies should compare results in vitamin D deficient patients to those in vitamin D sufficient patients.